Alemtuzumab Biosimilars(Cellectis)

N/A

Report date: 2024/08/28 20:00:53

Base Information

Drug NameAlemtuzumab Biosimilars(Cellectis)

Drug Alias NameCLLS52CLLS-52

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionCAMPATH-1 antigen inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effects

TargetsCAMPATH-1 antigen

Therapy Area/IndicationsLymphoma, B-CellLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceSpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCellectis Sa

China Registration ClassN/A

Develop Information

Active CompaniesCellectis Sa

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A